- Conditions
- Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic
- Interventions
- FOLFIRNINOX, Losartan, 9-ING-41
- Drug
- Lead sponsor
- Colin D. Weekes, M.D., PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Boston, Massachusetts • Charlestown, Massachusetts + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 241–264
of 589
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Solid Tumors
- Interventions
- Binimetinib, Encorafenib, Vemurafenib, Ribociclib, Cetuximab, Pembrolizumab, Nivolumab, 5-Fluorouracil, Leucovorin, Oxaliplatin, Irinotecan, Capecitabine, Bevacizumab
- Drug · Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Atlanta, Georgia • Boston, Massachusetts + 5 more
- Conditions
- Metastatic Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma
- Interventions
- Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil, Leucovorin, Gemcitabine (mg/m²), Nab-paclitaxel, Cisplatin
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- Charleston, South Carolina
- Conditions
- Metastatic Pancreas Adenocarcinoma
- Interventions
- 5FU, nab-paclitaxel, bevacizumab, calcium leucovorin, oxaliplatin
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 7
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Ann Arbor, Michigan + 4 more
- Conditions
- Metastatic Biliary Tract Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Digestive System Neoplasm, Metastatic Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
- Interventions
- Fluorouracil, Irinotecan Sucrosofate, Laboratory Biomarker Analysis, Leucovorin Calcium, Rucaparib
- Drug · Other
- Lead sponsor
- Academic and Community Cancer Research United
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Atlanta, Georgia • Rochester, Minnesota
- Conditions
- Pancreatic Adenocarcinoma, Borderline Resectable Adenocarcinoma of the Head of the Pancrease
- Interventions
- radiation therapy, surgery, mFOLFIRINOX, FOLFOX
- Radiation · Procedure · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2016
- U.S. locations
- 154
- States / cities
- Mobile, Alabama • Antioch, California • Berkeley, California + 122 more
- Conditions
- Colon Adenocarcinoma, Rectal Adenocarcinoma
- Interventions
- Calderasib, Oxaliplatin, Leucovorin/levofolinate calcium, 5-Fluorouracil, Cetuximab, Bevacizumab, Bevacizumab biosimilar
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 477 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 48
- States / cities
- Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 43 more
- Conditions
- Colorectal Cancer
- Interventions
- 5-Fluorouracil, Leucovorin, Capecitabine [Xeloda]
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,987 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2004
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 14 more
- Conditions
- Colon Cancer, Rectal Cancer
- Interventions
- FOLFOX6, RT with concurrent chemotherapy, Surgery
- Drug · Radiation · Procedure
- Lead sponsor
- William Sikov MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 3
- States / cities
- Pawtucket, Rhode Island • Providence, Rhode Island
- Conditions
- Pancreatic Cancer
- Interventions
- FOLFIRINOX, Losartan, Nivolumab, SBRT, Surgery
- Drug · Radiation · Procedure
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 10
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Baltimore, Maryland + 4 more
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
- Interventions
- MEK inhibitor MEK162, leucovorin calcium, fluorouracil, oxaliplatin, pharmacological study, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Inavolisib, Bevacizumab, Cetuximab, Atezolizumab, Tiragolumab, SY-5609, Divarasib, FOLFOX, FOLFIRI, FoundationOne®Liquid CDx
- Drug · Diagnostic Test
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 542 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 28 more
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
- Interventions
- fluorouracil, leucovorin calcium, vorinostat, pharmacological study
- Drug · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Gastric or Gastroesophageal Junction Adenocarcinoma
- Interventions
- Utidelone Capsule, Fluoropyrimidine- and Platinum-containing Therapy, Oxaliplatin, PD-1 inhibitor, Capecitabine
- Drug
- Lead sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 778 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Hialeah, Florida
- Conditions
- Cancer
- Interventions
- Paclitaxel, 5-Fluorouracil (5FU), Carboplatin, Leucovorin, Irinotecan, BMS-906024
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Solid Tumor, Colorectal Cancer, Non Hodgkin Lymphoma, Sarcoma, Chondrosarcoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
- Interventions
- Aplitabart (IGM-8444), FOLFIRI, Bevacizumab (and approved biosimilars), Birinapant, Venetoclax, Gemcitabine, Docetaxel, Azacitidine
- Drug
- Lead sponsor
- IGM Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Duarte, California • Los Alamitos, California + 29 more
- Conditions
- Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- Interventions
- Subcutaneous Tislelizumab, Intravenous Tislelizumab, Cisplatin, Leucovorin, 5-fluorouracil (5-FU), Oxaliplatin, Capecitabine
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 351 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 19
- States / cities
- Chandler, Arizona • Los Alamitos, California • Colorado Springs, Colorado + 16 more
- Conditions
- Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
- Interventions
- AZD0901, 5-Fluorouracil, Leucovorin, l-leucovorin, Irinotecan, Nanoliposomal Irinotecan, Gemcitabine
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 7
- States / cities
- Orange, California • Palo Alto, California • Santa Rosa, California + 4 more
- Conditions
- Colorectal Cancer
- Interventions
- 5-FU, Oxaliplatin, leucovorin, mesorectal excision
- Drug · Procedure
- Lead sponsor
- Beth Israel Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Adenocarcinoma of Pancreas
- Interventions
- Irinotecan, Oxaliplatin, Leucovorin, 5-FU
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Colorectal Neoplasms
- Interventions
- 5-fluorouracil
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Breast Cancer, Breast Neoplasms
- Interventions
- methotrexate, leucovorin, 5-fluorouracil, cyclophosphamide, peripheral blood progenitor cell, paclitaxel, doxorubicin
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Stage I Colon Cancer, Stage II Colon Cancer, Stage III Colon Cancer
- Interventions
- Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2, Oxaliplatin injection 85mg/m2 + Leucovorin 400mg/m2 + 5-Fluorouracil 2400mg/m2, Oxaliplatin 130mg/m2 + Capecitabine 1000mg/m2
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Colorectal Cancer
- Interventions
- bevacizumab, fluorouracil, irinotecan hydrochloride, leucovorin calcium, Oxaliplatin
- Biological · Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 247 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2015
- U.S. locations
- 110
- States / cities
- Greenbrae, California • Aurora, Colorado • Boulder, Colorado + 76 more